An Introduction to Drug Safety & Pharmacovigilance
This CE is intended for pharmacists. It will provide an overview of Drug Safety and pharmacovigilance (PV).
The session will enhance pharmacist’s knowledge of this specialized field in the pharmaceutical/biotech industry and increase awareness of the topic, as well as highlight potential career pivots.
Learning Objectives
At the completion of this activity, the participant should be able to:
- Describe terminology used in the field of Drug Safety and Pharmacovigilance.
- Explain the main components of Drug Safety and Pharmacovigilance and their interconnection with other industry functions.
- Follow a case safety report through the standard reporting channels.
- Recognize the impact Drug Safety and Pharmacovigilance has on patient safety and public health.
Presenter
Chantal Kosmidis, PharmD, has extensive experience in the field of Pharmacovigilance, with over twenty years in clinical trial development and post-marketing safety/pharmacovigilance exposure across a variety of drug lifecycle phases. She received her PharmD from MCPHS.
Course Fee: Free for MCPHS alumni, full-time staff, and for all other professionals.
Release Date: April 8, 2024
Expiration Date: April 8, 2025
ACPE UAN: 0026-0000-24-010-H05-P | Knowledge
Topic Designator: Patient Safety
Contact Hours: 1 (0.1 CEU)
Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Massachusetts College of Pharmacy and Health Sciences designates this educational activity for a total of 1 contact hours (0.1 CEUs).
In order to receive credit, the participant must view the entire presentation and complete the pre and post-tests, and evaluation form. Upon completion, participant credit will be reported to CPE Monitor. Transcripts may be printed from CPE Monitor.
Massachusetts College of Pharmacy and Health Sciences adheres to the ACPE Standards for Integrity and Independence in Continuing Education. It is the policy of MCPHS that the speakers and planning committee members disclose all financial relationships with ineligible companies within the last 24 months, and that relevant conflicts of interest are mitigated. Speakers will disclose any off-label/unapproved use of drugs or devices during their presentation.
Chantal Kosmidis, PharmD, holds a relevant financial relationship with the ineligible company Ipsen, where she is an employee. She was previously an employee of Sage Therapeutics and Biogen. The content developed does not endorse the product lines or solutions produced or offered by Ipsen, Sage Therapeutics, or Biogen.
Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies, related to the content of this presentation.
No funding from industry provided for this event. No exhibitors will be present